October 2014
Merck KGaA acquiring Sigma-Aldrich to enhance position in increasingly attractive life-sciences market...
by Jeffrey Bouley

October 2014
Mayo Clinic and IBM to apply Watson to clinical trial enrollment...
by Kelsey Kaustinen

October 2014
Blueprint Medicines announces discovery of novel oncology drug targets...
by Jeffrey Bouley

September 2014
RP101 has been granted Orphan Drug designation for the adjunct treatment of pancreatic cancer by FDA and EMA ...
by Lloyd Dunlap

September 2014
Oral treatment for spinal muscular atrophy appears effective in mice ...
by Zack Anchors

September 2014
Scripps Research Institute scientists find that cancer drug rapamycin may help bypass blood stem cell defenses...
by Lori Lesko



Show Preview:
Society for Neuroscience (SfN) 44th Annual Meeting
A Capitol affair
Society for Neuroscience stays in its own backyard (Washington, D.C.) for this year’s annual meeting, looking to host more than 30,000 attendees
(Click here to view our full pre-show coverage)
 

From ISSCR 2014, here are  reports from the field by DDNews Features Editor Randall C Willis ...
 
"Taking stem cells from bench to business"
"Building a better model"
"Shifting stem cell regulatory landscape"
"Patients' growing impatience for cell therapies"

 Our 2015 Media Kit is now available
 
 

 
Your gateway to the latest oncology news, trends and resources


October 2014
The ability to create isogenic cell lines in which the genome editing event is the sole differentiator between the phenotypes of two cells is a powerful tool. Despite all the recent developments and improvements in targeting platforms, certain challenges remain, and the role played by the choice of cell line in order to achieve success cannot be overstated... [ more ]
by Eric Rhodes & Dr. Jon Moore

October 2014
In an era of "publish or perish," combined with "fund or perish," we may be moving toward an era in which peer review is no longer up to the task, and we end up with too many journals and too little rigor.. [ more ]
by Peter T. Kissinger

October 2014
The effort to reduce obesity (and to profit from that effort) isn’t anything new, but based on my email inbox recently, perhaps we’re about to enter into an era of blockbuster weight-management medications. For the moment, however, we’re at the early stages of any such race, and it looks like Novo Nordisk and Orexigen are fighting for the strong start out of the gate... [ more ]
by Jeffrey Bouley